Repligen

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Repligen (RGEN) reports strong 2022 performance, eyes growth amid challenges

Repligen anticipates a challenging yet optimistic year in 2023, with revenue guidance of $760-800 million and adjusted EPS of $2.61-2.69 per fully diluted share. The company remains focused on organic growth, innovation, and strategic acquisitions to navigate industry headwinds.

Repligen reports Q1 revenue growth, eyes China rebound and new products

Repligen's Q1 2023 performance saw revenue growth but overall revenues declined due to reduced COVID-related demand.
Despite challenges in China and revised guidance, strategic investments and confidence in future growth opportunities remain strong.
The company is focused on new product launches, pricing resilience, and addressing challenges to drive growth and margin improvement.

Repligen faces revenue decline and margin pressure, eyes growth strategies

Repligen faces challenges in revenue decline and margin compression but is focusing on cost control and new product launches for growth.
Diversified revenue streams and positive developments in orders and integration provide a foundation for future opportunities.
Market dynamics and pharma spend challenges pose uncertainties, but the company remains optimistic about growth prospects.
Visibility improvements, margin recovery expectations, and pricing strategies are key focus areas for future profitability.

Repligen sees recovery in Q3 amidst industry challenges and restructuring

Repligen's Q3 2023 showed signs of recovery amidst industry challenges, with a focus on cost optimization and new product launches. The company incurred restructuring charges to streamline operations and expects improved margins in 2024. Despite revenue declines, opportunities lie in the gene therapy segment and future recovery in China.

Repligen reports Q4 revenue decline but eyes growth in China

Repligen's Q4 2023 showed mixed results with revenue decline but sequential growth. The company is focusing on profitability improvements in 2024 and anticipates growth driven by new modalities and market recovery. Challenges in revenue performance are being addressed, with a strategic focus on key account management and cost containment.

Repligen reports mixed Q1 results, focuses on innovation and growth

Repligen's Q1 2024 performance showed mixed results with revenue declines but positive growth in key segments. The company maintains its focus on innovation, cost control, and strategic expansion while navigating challenges in profitability. Opportunities lie in market improvements and growth potential in new modalities.

Repligen reports strong Q2 performance, eyes robust growth ahead

Repligen's Q2 2024 earnings call showcased strong performance in pharma and consumables, despite challenges from China and foreign exchange. The company anticipates a return to robust revenue growth in the second half of the year and is optimistic about future growth prospects.

Repligen (RGEN) reports robust Q3 results and eyes 2025 growth

Repligen is on track to meet 2024 revenue guidance, entering 2025 in a strong position.
Exciting product launches planned for 2025 across all business units.
Strong start to Q4 with confidence in meeting financial targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Repligen (RGEN) Q4 Earnings Expected to Decline

Alliance Resource Partners

Incyte

These three stocks have major events coming up this month -- and it's not just the release of earnings that investors will be watching.

Stocks to Watch in February

Catalent

These companies aren't household names, but they quietly enable customers across the pharmaceutical and biopharmaceutical sectors to bring innovative new products to market.

2 Stocks to  Buy and Hold for Decades

Repligen Gives Investors A Pure Play On Bioproduction

ABIOMED

ACADIA Pharma

Accelerate Diagnostics

DexCom

Exact Sciences

Jazz Pharmaceuticals

Neurocrine Biosciences

NeoGenomics

Simulations Plus

The 10 Best Healthcare Stocks of the Decade

Repligen (RGEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Growth Investors Will Love Repligen (RGEN)

Does Repligen (RGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Repligen (RGEN) is a Great Momentum Stock to Buy

Align Technology

Edwards Lifesciences

Globus Medical

LeMaitre Vascular

QuidelOrtho Corp

ResMed

Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs.

These Medical Stocks Are Outperforming 95% Of All Stocks — Here's Why

Repligen keeps growing revenues; by 40% yoy in Q319, and at a CAGR of 27% between FY 2016 and FY 2019 (if full-year revenue targets are met).

Repligen Stock Price Can Keep Growing: Buy The Current Dip

Repligen Corporation (RGEN) CEO Tony Hunt on Q3 2019 Results - Earnings Call Transcript

Repligen (RGEN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance

The company, which has been built on opportunistic acquisitions, entered the final stretch of 2019 with a record level of cash to deploy.

Repligen Exits Third Quarter Armed With a $500 Million War Chest

Repligen (RGEN) Reports Next Week: What to Expect

The year may be drawing to a close, but this biomanufacturing stock -- and any investor interested in it -- has plenty to look forward to.

3 Things Repligen Investors Need to Watch

Sometimes stocks go up, sometimes they go down.

Here's Why Repligen Stock Tumbled 17.4% in September

The bioprocessing leader is having a bad day, but there doesn't appear to be any reason to panic.

Here's Why Repligen Has Dropped as Much as 13.1% Today

TerraForm Power

Trex

These businesses offer the potential for above-average returns that could receive a huge helping hand from the power of compound interest.

Three Stocks to Buy and Hold for Decades.

DocuSign

Wayfair

Investors looking to grow their nest egg should give these three stocks a closer look.

3 Growth Stocks - for In-the-Know Investors.

The bioprocess leader keeps growing at an incredible pace thanks to acquisitions and surging customer demand.

Repligen Grows Revenue 48% in Q2

Repligen Corporation (RGEN) CEO Tony Hunt on Q2 2019 Results - Earnings Call Transcript

Chegg

Delta Air Lines

Boston Beer Company

Teledyne Technologies

Although market participants were expecting a quarter percentage point of cut, they were taken aback by Fed Chair Jerome Powell's comment that this rate cut is "in the nature of a mid-cycle adjustment to policy."

Powell Gives Space for Growth, Market Overreacts:  5 Picks

Rent-A-Center

Sunoco

Telephone and Data Systems

Tandem Diabetes Care

A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.

5 Top Picks on Three Key Takeaways From Q2 U.S. GDP

On Repligen's (RGEN) second-quarter earnings call, investor focus will be on its advancement with the proposed acquisition of C Technologies, Inc.

Is a Beat in Store for Repligen (RGEN) This Earnings Season?

The bioprocess engineering leader continued to deliver spectacular growth and bolster its profitability.

Here's Why Repligen Gained 62.9% in the First Half of 2019

Repligen (RGEN) could produce exceptional returns because of its solid growth attributes.

News for Repligen Stock (RGEN)